A market research firm forecasts that more drug-eluting stents are on the way, which will bring down the costs of these devices.
Medtronic’s drug-eluting stent (DES), Endeavor, launched in the first quarter of this year, has gained considerable market share. But more DESs are expected to be approved later this year, including Abbott Vascular’s XIENCE V, Boston Scientific’s PROMUS, and next-generation TAXUS Liberte. Prices will drop as a result, especially since PROMUS and XIENCE V are identical. These are some conclusions from the Millennium Research Group’s Interventional Cardiology Marketrack.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.